Device Therapy for Rate Control: Pacing, Resynchronisation and AV Node Ablation
Standard
Device Therapy for Rate Control: Pacing, Resynchronisation and AV Node Ablation. / Lau, Dennis H; Thiyagarajah, Anand; Willems, Stephan; Rostock, Thomas; Linz, Dominik; Stiles, Martin K; Kaye, David; Kalman, Jonathan M; Sanders, Prashanthan.
in: HEART LUNG CIRC, Jahrgang 26, Nr. 9, 09.2017, S. 934-940.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Device Therapy for Rate Control: Pacing, Resynchronisation and AV Node Ablation
AU - Lau, Dennis H
AU - Thiyagarajah, Anand
AU - Willems, Stephan
AU - Rostock, Thomas
AU - Linz, Dominik
AU - Stiles, Martin K
AU - Kaye, David
AU - Kalman, Jonathan M
AU - Sanders, Prashanthan
N1 - Crown Copyright © 2017. Published by Elsevier B.V. All rights reserved.
PY - 2017/9
Y1 - 2017/9
N2 - Atrioventricular node ablation (AVNA) is generally reserved for patients whose atrial fibrillation (AF) is refractory all other therapeutic options, since the recipients will often become pacemaker dependent. In such patients, this approach may prove particularly useful, especially if a tachycardia-induced cardiomyopathy is suspected. Historically, an "ablate and pace" approach has involved AVNA and right ventricular pacing, with or without an atrial lead. There is also an evolving role for atrioventricular node ablation in patients with AF who require cardiac resynchronisation therapy for treatment of systolic heart failure. A mortality benefit over pharmacotherapy has been demonstrated in observational studies and this concept is being further investigated in multi-centre randomised control trials.
AB - Atrioventricular node ablation (AVNA) is generally reserved for patients whose atrial fibrillation (AF) is refractory all other therapeutic options, since the recipients will often become pacemaker dependent. In such patients, this approach may prove particularly useful, especially if a tachycardia-induced cardiomyopathy is suspected. Historically, an "ablate and pace" approach has involved AVNA and right ventricular pacing, with or without an atrial lead. There is also an evolving role for atrioventricular node ablation in patients with AF who require cardiac resynchronisation therapy for treatment of systolic heart failure. A mortality benefit over pharmacotherapy has been demonstrated in observational studies and this concept is being further investigated in multi-centre randomised control trials.
KW - Atrial Fibrillation/physiopathology
KW - Atrioventricular Node/surgery
KW - Cardiac Pacing, Artificial/methods
KW - Cardiac Resynchronization Therapy/methods
KW - Catheter Ablation/methods
KW - Heart Rate/physiology
KW - Humans
U2 - 10.1016/j.hlc.2017.05.124
DO - 10.1016/j.hlc.2017.05.124
M3 - SCORING: Review article
C2 - 28687248
VL - 26
SP - 934
EP - 940
JO - HEART LUNG CIRC
JF - HEART LUNG CIRC
SN - 1443-9506
IS - 9
ER -